Free Trial

Corvus Pharmaceuticals (CRVS) News Today

Corvus Pharmaceuticals logo
$3.20 -0.15 (-4.33%)
Closing price 03:59 PM Eastern
Extended Trading
$3.20 0.00 (0.00%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRVS Latest News

Corvus Pharmaceuticals, Inc. stock logo
74,307 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Acquired by Acuta Capital Partners LLC
Acuta Capital Partners LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 74,307 shares of the company's stock, valued at approximately $398,000. Acuta Ca
Corvus Pharmaceuticals, Inc. stock logo
Foresite Capital Management VI LLC Buys New Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Foresite Capital Management VI LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,581,233 shares of the company's stock, valued at approximately $8,460,000. Corvus Pharmace
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Monday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-corvus-pharmaceuticals-inc-stock/)
Corvus Pharmaceuticals, Inc. stock logo
Vivo Capital LLC Has $11.96 Million Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Vivo Capital LLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,234,566 shares of the company's stock a
Corvus Pharmaceuticals, Inc. stock logo
Raymond James Financial Inc. Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Raymond James Financial Inc. purchased a new stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,989 shares of the company's stock, valued at app
Corvus Pharmaceuticals, Inc. stock logo
HC Wainwright Has Optimistic View of CRVS FY2025 Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals, Inc. stock logo
HC Wainwright Issues Pessimistic Forecast for CRVS Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright dropped their FY2028 earnings estimates for Corvus Pharmaceuticals in a research report issued on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings per s
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday.
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings Results
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06).
Corvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)
Corvus Pharmaceuticals, Inc. stock logo
EntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 116,645 shares of the company's stock,
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from Analysts
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has received a consensus recommendation of "Buy" from the five analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (CRVS) to Release Earnings on Tuesday
Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Buy" by Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has given a strong
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from Brokerages
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong
Corvus Pharmaceuticals, Inc. stock logo
Cantor Fitzgerald Forecasts CRVS FY2025 Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Corvus Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals (NASDAQ:CRVS) Receives "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday.
Corvus announces data from cohort 2 of Phase 1 trial of Soquelitinib
Corvus Pharmaceuticals, Inc. stock logo
Geode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
Geode Capital Management LLC boosted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 22.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 563,009 shar
Corvus Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for CRVS FY2024 Earnings?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company w
Corvus Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Estimate for CRVS Q4 Earnings?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 EPS estimates for Corvus Pharmaceuticals in a research report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of ($
Corvus Pharmaceuticals initiated with a Buy at H.C. Wainwright
Corvus Pharmaceuticals, Inc. stock logo
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the four analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a buy recommendation and one has given a strong buy recommen
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment

1.14

0.64

Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week

1

2

CRVS Articles
Average Week

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CRVS) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners